Distribution, biochemistry and function of striatal adenosine A(2A) receptors

Progress in Neurobiology

Volumn 59, Issue 4, 1999, Pages 355-396

  Svenningsson, Per ^a   Le Moine, Catherine ^b   Fisone, Gilberto ^a   Fredholm, Bertil B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENYLATE CYCLASE; AMPHETAMINE; CAFFEINE; COCAINE; CYCLIC AMP; DIZOCILPINE; DRONABINOL; MESSENGER RNA; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINE; PHENCYCLIDINE; QUINOXALINE; THEOPHYLLINE; XANTHINE DERIVATIVE;

ANXIETY; BASAL GANGLION; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; GENE EXPRESSION; NEUROPROTECTION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SLEEP;

ANIMALS; NEOSTRIATUM; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1;

EID: 0032781426     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(99)00011-8     Document Type: Review

References (442)

1. Abbracchio M.P., Colombo F., Di Luca M., Zaratin P., Cattabeni F. Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. Pharmac. Res. Commun. 19:1987;275-286.
2. Adami M., Bertorelli R., Ferri N., Foddi M.C., Ongini E. Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmac. 294:1995;383-389.
3. Afonso S., O'Brien G.S. Inhibition of cardiovascular metabolic and hemodynamic effects of adenosine by aminophylline. Am. J. Physiol. 219:1970;1672-1674.
4. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
5. Alexander S.P., Reddington M. The cellular localization of adenosine receptors in rat striatum. Neuroscience. 28:1989;645-651.
6. Aleid G.F., Heimer L. Theories of basal forebrain organization and the "emotional motor system" Prog. Brain Res. 107:1996;461-484.
7. Andén N-E., Carlsson A., Dahlström A., Fuxe K., Hillarp N-Å., Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3:1964;523-530.
8. Anderson C.M., Xiong W., Young J.D., Cass C.E., Parkinson F.E. Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. Brain Res. Mol. Brain Res. 42:1996;358-361.
9. Arch J.R., Newsholme E.A. The control of the metabolism and the hormonal role of adenosine. Essays Biochem. 14:1978;82-123.
10. 2A receptors upon NGF-induced differentiation of PC 12 cells. Neuropharmacology. 36:1997;1319-1326.
11. 2A receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res. Mol. Brain Res. 22:1994;204-210.
12. Ballarin M., Herrera-Marschitz M., Casas M., Ungerstedt U. Striatal adenosine levels measured in vivo by microdialysis in rats with unilateral dopamine denervation. Neurosci Lett. 83:1987;338-344.
13. Ballarin M., Fredholm B.B., Ambrosio S., Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand. 142:1991;97-103.
14. Barraco R.A., Bryant S.D. Depression of locomotor activity following bilateral injections of adenosine analogs into the striatum of mice. Med. Sci. Res. 15:1987;421-422.
15. Barraco R.A., Coffin V.L., Altman H.J., Phillis J.W. Central effects of adenosine analogs on locomotor activity in mice and antagonism of caffeine. Brain Res. 272:1983;392-395.
16. 2A receptors in the nucleus accumbens. Prog Neuropsychopharmacol. Biol. Psychiatry. 18:1994;545-553.
17. 2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc. Natl. Acad. Sci. USA. 86:1989;6572-6576.
18. 2-adenosine receptor binding subunit. Mol. Pharmac. 38:1990;177-183.
19. Beckstead R.M., Cruz C.J. Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience. 19:1985;147-158.
20. Beckstead R.M., Kersey K.S. Immunohistochemical demonstration of differential substance P-, met-enkephalin-, and glutamic-acid-decarboxylase-containing cell body and axon distributions in the corpus striatum of the cat. J. comp. Neurol. 232:1985;481-498.
21. Bedingfield J.B., King D.A., Holloway F.A. Cocaine and caffeine: Conditioned place preference, locomotor activity, and additivity. Pharmac. Biochem. Behav. 61:1998;291-296.
22. Bennett H.J., Semba K. Immunohistochemical localization of caffeine-induced c-Fos protein expression in the rat brain. J. comp. Neurol. 401:1998;89-108.
23. 2 receptors in the human ventral striatum. Neurosci. Lett. 150:1993;75-79.
24. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J. Neurosci. 18:1998;5301-5310.
25. Berne R.M., Rubio R., Curnish R.R. Release of adenosine from ischemic brain. Circ. Res. 35:1974;262-271.
26. Berretta S., Robertson H.A., Graybiel A.M. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J. Neurophysiol. 68:1992;767-777.
27. 2A adenosine receptors on sleep-waking patterns in rats. Drug. Dev. Res. 37:1996;65-72.
28. 1 receptors in the basal ganglia of the cat and primate: delineation of striosomal compartments and pallidal and nigral subdivisions. Neuroscience. 26:1988;101-119.
29. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77.
30. Boissier J.R., Simon P. Action de la cafeine sur la motilite spontanee de la souris. Arch. Int. Pharmacodyn. Ther. 158:1965;212-221.
31. Bona E., Åden U., Gilland E., Fredholm B.B., Hagberg H. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology. 36:1997;1327-1338.
32. Bonci A., Williams J.T. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron. 16:1996;631-639.
33. Booth R.G., Balderassi R.J. Adenosine A2 stimulation of tyrosine hydroxylase in rat striatal minces is reversed by dopamine D2 autoreceptor activation. Eur. J. Pharmac. 185:1990;217-221.
34. Boulenger J.P., Uhde T.W., Wolff E.A., Post R.M. Increased sensitivity to caffeine in patients with panic disorders. Arch. Gen. Psychiat. 41:1984;1067-1071.
35. 1 dopamine receptor in humans. J. comp. Neurol. 370:1996;23-34.
36. 2 dopamine receptor in humans: an in situ hybridization and receptor-binding study. Brain Res. Mol. Brain Res. 48:1997;389-400.
37. 6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J. Med. Chem. 30:1987;1709-1711.
38. Broch O.J., Ueland P.M. Regional and subcellular distribution of S-adenosylhomocysteine hydrolase in the adult rat brain. J. Neurochem. 35:1980;484-488.
39. 2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav. Pharmac. 7:1996;373-383.
40. Brockwell N.T., Eikelboom R., Beninger R.J. Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmac. Biochem. Behav. 38:1991;513-517.
41. Brodie M.S., Lee K., Fredholm B.B., Ståhle L., Dunwiddie T.V. Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action. Brain Res. 415:1987;323-330.
42. 2a purine receptors regulate striatal acetylcholine release. J. Neurochem. 55:1990;31-38.
43. 2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation. Psychopharmacology (Berl.). 103:1991;78-82.
44. Brundege J.M., Dunwiddie T.V. Modulation of excitatory synaptic transmission by adenosine released from single hippocampal pyramidal neurons. J. Neurosci. 16:1996;5603-5612.
45. Brundege J.M., Diao L., Proctor W.R., Dunwiddie T.V. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology. 36:1997;1201-1210.
46. 3H]-NECA in rat striatal membranes. Mol. Pharmac. 29:1986;331-346.
47. 1 receptor distribution. Brain Res. Dev. Brain Res. 58:1991;111-122.
48. 1 receptor in the rat striatonigral system: an immunohistochemical study. Eur. J. Neurosci. 7:1995;714-722.
49. Calabresi P., Centonze D., Pisani A., Bernardi G. Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J. Neurosci. 17:1997;4509-4516.
50. van Calker D., Muller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:1979;999-1005.
51. Carswell H.V., Graham D.I., Stone T.W. Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: possible involvement of free radicals. J. Neurochem. 68:1997;240-247.
52. Cartmell J., Schaffhauser H., Wichmann J., Mutel V. mGluR-evoked augmentation of receptor-medated cyclic AMP formation in neonatal and adult rat striatum. Br. J. Pharmac. 121:1997;1263-1268.
53. Casas M., Ferré S., Guix T., Jane F. Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis. Biol. Psychiat. 24:1988;642-648.
54. Cenci M.A., Campbell K., Wictorin K., Björklund A. Striatal c-fos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat. Eur. J. Neurosci. 4:1992;376-380.
55. 2A adenosine receptor increases expression of the tyrosine hydroxylase gene. Brain Res. Mol. Brain Res. 44:1997;31-38.
56. Chang S.L., Squinto S.P., Harlan R.E. Morphine activation of c-fos expression in rat brain. Biochem. Biophys. Res. Commun. 157:1988;698-704.
57. 2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells. J. Neurochem. 69:1997;1300-1309.
58. Charney D.S., Heninger G.R., Jatlow P.I. Increased anxiogenic effects of caffeine in panic disorders. Arch. Gen. Psychiat. 42:1985;233-243.
59. 2A adenosine receptor inhibit adenosine agonist-induced catalepsy in rats. J. Neurochem. 65:1995;S26.
60. 2 dopamine receptor mRNA in rat corpus striatum. Brain Res. Dev. Brain Res. 63:1991;95-104.
61. Chen J.F., Moratalla R., Turner T., Xu Y.H., Beilstein M., Standaert D., Penney J., Fink J.S., Schwarzschild M.A. Deficiency of the A2a adenosine receptor attenuates striatal dopamine release as well as spontanous and amphetamine-induced locomotion. Soc. Neurosci. Abstr. 24:1998;824.11.
62. Chergui K., Svenningsson P., Nomikos G.G., Gonon F., Fredholm B.B., Svennson T.H. Increased expression of NGFI-A mRNA in the rat striatum following burst stimulation of the medial forebrain bundle. Eur. J. Neurosci. 9:1997;2370-2382.
63. Chern Y., King K., Lai H. Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem. Biophys. Res. Commun. 185:1992;304-309.
64. Chern Y., Lai H.L., Fong J.C., Liang Y. Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC 12 cells. Mol. Pharmac. 44:1993;950-958.
65. 2a adenosine receptor-mediated cyclic AMP response: role for protein phosphatase 2A. Mol. Pharmac. 48:1995;1-8.
66. 2+-inhibitable adenylyl activity of the rat striatum. FEBS Lett. 385:1996;205-208.
67. Chiasson B.J., Hooper M.L., Murphy P.R., Robertson H.A. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmac. 227:1992;451-453.
68. 2 receptors. Brain Res. 761:1997;151-155.
69. 2a adenosine receptor gene. DNA Cell. Biol. 15:1996;329-337.
70. Coffin V.L., Taylor J.A., Phillis J.W., Altman H.J., Barraco R.A. Behavioral interaction of adenosine and methylxanthines on central purinergic systems. Neurosci. Lett. 47:1984;91-98.
71. Cole R.L., Konradi C., Douglass J., Hyman S.E. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron. 14:1995;813-823.
72. Colwell C.S., Levine M.S. Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms. J. Neurosci. 15:1995;1704-1713.
73. 2 sites in Parkinson syndrome with different etiology. Brain Res. 438:1989;30-38.
74. 2a receptors in the rat hippocampus. Brain Res. 649:1994;208-216.
75. 2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport. 6:1995;1583-1588.
76. 2A receptors. Naunyn Schmiedeberg's Arch. Pharmac. 353:1996;261-271.
77. 2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus. Br. J. Pharmac. 122:1997;1279-1284.
78. Dahlström A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamine in the cell bodies of the brain stem neurons. Acta Physiol. Scand. 62:1964;1-55.
79. Daly J.W. Cyclic nucleotides in the nervous system. Iversen L.L., Iversen S.D., Snyder S.H. Handbook of Psychopharmacology. vol. 5:1977;47-130 Plenum Press, New York.
80. Daly J.W. Mechanism of action of caffeine. Garattini S. Caffeine, Coffee, and Health. 1993;97-150 Raven Press, New York.
81. Daly J.W., Butts-Lamb P., Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 3:1983;69-80.
82. 2 receptors in stably cotransfected fibroblast cells. Eur. J. Pharmac. 316:1996;325-331.
83. Datta U., Noailles P.A., Kraft M., Zhang Y., Angulo J.A. Concurrent elevation of the levels of expression of striatal preproenkephalin and preprodynorphin mRNA in the rat brain by chronic treatment with caffeine. Neurosci. Lett. 231:1997;29-32.
84. 2 receptors? Pharmac. Ther. 71:1996;325-335.
85. De Gubareff T., Sleator W. Jr. Effects of caffeine on mammalian atrial muscle, and its interaction with adenosine and calcium. J. Pharmac. exp. Ther. 148:1965;202-214.
86. 2a receptor (A2aAR) gene: systematic mutation screening in patients with schizophrenia. J. Neural. Transm. 103:1996;1447-1455.
87. 2a gene to the development of disease. Mol. Psychiat. 3:1998;81-85.
88. Delaney S.M., Geiger J.D. Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J. Pharmac. exp. Ther. 285:1998;568-572.
89. Delaney S.M., Shepel P.N., Geiger J.D. Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. J. Pharmac. exp. Ther. 285:1998;561-567.
90. Deniau J.M., Feger J., Le Guyader C. Striatal evoked inhibition of identified nigro-thalamic neurons. Brain Res. 104:1976;152-156.
91. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmac. 118:1996;1461-1468.
92. 2A receptor in the rat striatum. J. Neurochem. 69:1997;315-321.
93. Dolphin A.C., Archer E.R. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. Neurosci. Lett. 43:1983;49-54.
94. Donoghue J.P., Herkenham M. Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. Brain Res. 365:1986;397-403.
95. Dragunow M., Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Meth. 29:1989;261-265.
96. Dragunow M., Robertson H.A. Kindling stimulation induces c-fos protein(s) in granule cells of the rat dentate gyrus. Nature. 329:1987;441-442.
97. Dragunow M., Robertson H.A. Generalized seizures induce c-fos protein(s) in mammalian neurons. Neurosci. Lett. 82:1987;157-161.
98. 2 receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
99. Drury A.N., Szent-György A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (London). 68:1929;213-237.
100. Dunwiddie T.V. The physiological role of adenosine in the central nervous system. Int. Rev. Neurobiol. 27:1985;63-139.
101. Dunwiddie T.V., Fredholm B.B. Adenosine neuromodulation. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;359-382 Wiley-Liss, New York.
102. Dunwiddie T.V., Hoffer B.J. Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus. Br. J. Pharmac. 69:1980;59-68.
103. Dunwiddie T.V., Hoffer B.J., Fredholm B.B. Alkylxanthines elevate hippocampal excitability. Evidence for a role of endogenous adenosine. Naunyn-Schmiedeberg's Arch. Pharmac. 316:1981;326-330.
104. Dunwiddie T.V., Diao L., Proctor W.R. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J. Neurosci. 17:1997;7673-7682.
105. 2 receptor involvement in the hypomobility effects of adenosine analogues in mice. Eur. J. Pharmac. 168:1989;285-290.
106. Fallahi N., Broad R.M., Jin S., Fredholm B.B. Release of adenosine from rat hippocampal slices by the nitric oxide donor S-nitroso-N-acetylpenicillamine. J. Neurochem. 67:1996;186-193.
107. 2 receptors. Eur. J. Neurosci. 10:1998;1878-1884.
108. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmac. 321:1997;143-147.
109. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl.). 133:1997;107-120.
110. Ferré S., Herrera-Marschitz M., Grabowska-Andén M., Casas M., Ungerstedt U., Andén N.E. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur. J. Pharmac. 192:1991;31-37.
111. 2 receptors induces catalepsy. Neurosci. Lett. 130:1991;162-164.
112. 2 receptors in rat striatal membranes. Proc. natl Acad. Sci. USA. 88:1991;7238-7241.
113. Ferré S., O'Connor W.T., Fuxe K., Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13:1993;5402-5406.
114. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
115. 1 receptors. Neuroreport. 6:1994;73-76.
116. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8:1996;1545-1553.
117. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
118. 1 receptors in stably cotransfected fibroblast cells. J. Biol. Chem. 273:1998;4718-4724.
119. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W.J., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 281:1998;838-842.
120. 2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14:1992;186-195.
121. Fischer H., Prast H., Philippu A. Adenosine release in the ventral striatum of the rat is modulated by endogenous nitric oxide. Eur. J. Pharmac. 275:1995;R5-R6.
122. Fishel G., van der Kooy D. Pattern formation in the striatum: developmental changes in the distribution of striatonigral neurons. J. Neurosci. 7:1987;1969-1978.
123. Fredholm B.B. Activation of adenylate cyclase from rat striatum and tuberculum olfactorium by adenosine. Med. Biol. 55:1977;262-267.
124. Fredholm B.B. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmac. Sci. 1:1980;129-132.
125. Fredholm B.B. Adenosine actions and adenosine receptors after 1 Week treatment with caffeine. Acta Physiol. Scand. 115:1982;283-286.
126. Fredholm B.B. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmac. Toxic. 76:1995;93-101.
127. Fredholm B.B., Dunwiddie T.V. How does adenosine inhibit transmitter release? Trends Pharmac. Sci. 9:1988;130-134.
128. Fredholm B.B., Hedqvist P. Modulation of neurotransmission by purine nucleotides and nucleosides. Biochem. Pharmac. 29:1980;1635-1643.
129. Fredholm B.B., Fuxe K., Agnati L. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur. J. Pharmac. 38:1976;31-38.
130. Fredholm B.B., Herrera-Marschitz M., Jonzon B., Lindström K., Ungerstedt U. On the mechanism by which methylxanthines enhance apomorphine-induced rotation behaviour in the rat. Pharmac. Biochem. Behav. 19:1983;535-541.
131. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmac. Rev. 46:1994;143-156.
132. Fredholm B.B., Lindström K., Wallman-Johansson A. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices. J. Neurochem. 62:1994;563-573.
133. 2A receptors and the actions of caffeine. Okada Y. The Role of Adenosine in the Nervous System. 1997;51-74 Elsevier Science, Amsterdam.
134. Fredholm B.B., Johansson B., Lindström K., Wahlström G. Age-dependent changes in adenosine receptors are not modified by life-long intermittent alcohol administration. Brain Res. 791:1998;177-185.
135. 2A receptor antagonist, is a useful ligand in autoradiographic studies. J. Neurochem. 70:1998;1210-1216.
136. Fredholm B.B., Bättig K., Holmen J., Nehlig A., Zvartau E. Actions of caffeine in the brain with special reference to dependence. Pharmac. Rev. 51:1999;83-133.
137. 2 receptor. Brain Res. Mol. Brain Res. 15:1992;62-66.
138. Fuxe K., Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 52:1974;48-54.
139. Fuxe K., Fredholm B.B., Agnati L.F., Corrodi H. Dopamine receptors and ergot drugs: evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors. Brain Res. 146:1978;295-311.
140. 1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26:1998;258-273.
141. 2 receptor agonists but not to their synergistic interaction. Eur. J. Pharmac. 262:1994;65-75.
142. Garrett B.E., Holtzman S.G. Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J. Pharmac. exp. Ther. 274:1995;207-214.
143. Gerfen C.R. The neostriatal mosaic: striatal patch-matrix organization is related to cortical lamination. Science. 246:1989;385-388.
144. Gerfen C.R., Wilson C.J. The basal ganglia. Swanson L.W., Björklund A., Hökfelt T. Handbook of Chemical Neuroanatomy: Integrated systems of the CNS. 1996;371-467 Elsevier Science, Amsterdam.
145. Gerfen C.R., Young W.S. III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
146. Gerfen C.R., Baimbridge K.G., Miller J.J. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. natl Acad. Sci. USA. 82:1985;8780-8784.
147. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
148. 1-containing neurons. J. Neurosci. 15:1995;8167-8176.
149. Goldmann-Rakic P.S., Selemon L.D. New frontiers in basal ganglia research. Introduction. Trends Neurosci. 13:1990;241-244.
150. 2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res. 806:1998;202-209.
151. 1 receptors in the rat striatum in vivo. J. Neurosci. 17:1997;5972-5978.
152. Goodman R.R., Kuhar M.J., Hester L., Snyder S.H. Adenosine receptors: autoradiographic evidence for their location on axon terminals of excitatory neurons. Science. 220:1983;967-969.
153. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
154. Graybiel A.M., Ragsdale C.W. Jr. Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining. Proc. natl Acad. Sci. USA. 75:1978;5723-5726.
155. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. natl Acad. Sci. USA. 87:1990;6912-6916.
156. Green R.D., Proudfit H.K., Yeung S.M. Modulation of striatal dopaminergic function by local injection of 5′-N-ethylcarboxamide adenosine. Science. 218:1982;58-61.
157. Greengard P., Nairn A.C., Girault J.A., Ouimet C.C., Snyder G.L., Fisone G., Allen P.B., Fienberg A., Nishi A. The DARPP-32/protein phosphatase-1 cascade: a model for signal integration. Brain Res. Brain Res. Rev. 26:1998;274-284.
158. 2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice. Neuroreport. 2:1991;139-140.
159. 1-selective antagonist, DPCPX. Psychopharmacology (Berl.). 103:1991;541-544.
160. 2a receptor antagonist KW-6002 in Parkinson's disease. Soc. Neurosci. Abstr. 23:1997;1902.
161. Gubits R.M., Wollack J.B., Yu H., Liu W.K. Activation of adenosine receptors induces c-fos, but not c-jun, expression in neuron-glia hybrids and fibroblasts. Brain Res. Mol. Brain Res. 8:1990;275-281.
162. 2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J. Neurochem. 67:1996;374-381.
163. 2 dopamine receptor gene expression in the rat striatum during ontogeny: an in situ hybridization study. Brain Res. Dev. Brain Res. 60:1991;79-87.
164. 1 and DARPP-32 gene expresion in the rat striatum: an in situ hybrdization study. Brain Res. Mol. Brain Res. 15:1992;179-185.
165. Halpain S., Girault J.A., Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 343:1990;369-372.
166. 3H-noradrenaline from slices of rat brain neocortex. Eur. J. Pharmac. 49:1978;305-308.
167. Harms H.H., Wardeh G., Mulder A.H. Effect of adenosine on depolarization-induced release of various radiolabelled neurotransmitters from slices of rat corpus striatum. Neuropharmacology. 18:1979;577-580.
168. 1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J. Neurosci. 17:1997;5271-5280.
169. 2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport. 8:1997;1515-1518.
170. 2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors. Neurosci. Lett. 196:1995;205-208.
171. Hauber W., Münkle M. The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmac. 354:1996;179-186.
172. 2A receptors in the caudate-putamen. Neuroreport. 9:1998;1803-1806.
173. Hedqvist P., Fredholm B.B. Effects of adenosine on adrenergic neurotransmission; prejunctional inhibition and postjunctional enhancement. Naunyn-Schmiedeberg's Arch. Pharmac. 293:1976;217-223.
174. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Coughenour L.L., Downs D.A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berl.). 98:1989;31-37.
175. Hemmings H.C. Jr, Greengard P., Tung H.Y., Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 310:1984;503-505.
176. Herkenham M., Pert C.B. Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature. 291:1981;415-418.
177. 2+ conductance. J. Neurosci. 17:1997;3334-3342.
178. Herrera-Marschitz M., Casas M., Ungerstedt U. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology. 94:1988;38-45.
179. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
180. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15:1995;5222-5237.
181. 2A receptors in rat striatum: prevalent dendritic localization post-synaptic to catecholaminergic terminals. Soc. Neurosci. Abstr. 24:1998;821.7.
182. 2 agonist binding in the rat brain. Brain Res. 690:1995;34-40.
183. Holtzman S.G. CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats. Life Sci. 49:1991;1563-1570.
184. Holtzman S.G., Finn I.B. Tolerance to behavioral effects of caffeine in rats. Pharmac. Biochem. Behav. 29:1988;411-418.
185. Hooper M.L., Chiasson B.J., Robertson H.A. Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect. Neuroscience. 63:1994;917-924.
186. Horger B.A., Wellman P.J., Morien A., Davies B.T., Schenk S. Caffeine exposure sensitizes rats to the reinforcing effects of cocaine. Neuroreport. 2:1991;53-56.
187. 2 class receptors. Neurosci. Lett. 224:1997;61-65.
188. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
189. Huston J.P., Haas H.L., Boix F., Pfister M., Decking U., Schrader J., Schwarting R.K. Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats. Neuroscience. 73:1996;99-107.
190. 2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmac. exp. Ther. 251:1989;47-55.
191. 2A adenosine receptors in the rat superior colliculus in vivo. Brain Res. 757:1997;268-275.
192. 2-adenosine antagonist in vitro and in vivo. FEBS Lett. 323:1993;141-144.
193. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmac. 116:1995;2127-2133.
194. James S., Xuereb J.H., Askalan R., Richardson P.J. Adenosine receptors in post-mortem human brain. Br. J. Pharmac. 105:1992;238-244.
195. 3H]CGS 21680. Eur. J. Pharmac. 168:1989;243-246.
196. Jiang H., Jackson-Lewis V., Muthane U., Dollison A., Ferreira M., Espinosa A., Parsons B., Przedborski S. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res. 613:1993;347-351.
197. 2A adenosine receptors are required for ligand recognition. Mol. Pharmac. 50:1996;512-521.
198. 2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn-Schmiedeberg's Arch. Pharmac. 355:1997;48-56.
199. 2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmac. exp. Ther. 267:1993;801-808.
200. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology. 34:1995;393-403.
201. Johansson B., Svenningsson P., Åden U., Lindström K., Fredholm B.B. Evidence that the increase in striatal c-fos following acute high dose caffeine is not due to direct interaction with striatal adenosine receptors. Acta Physiol. Scand. 146:1992;539-541.
202. 2 adenosine receptor binding and on mRNA levels. Naunyn-Schmiedeberg's Arch. Pharmac. 347:1993;407-414.
203. 3H]CGS 21680 to rat cortex differs from its binding to rat striatum. Eur. J. Pharmac. 247:1993;103-110.
204. Johansson B., Herrera-Marschitz M., Svenningsson P., Fredholm B.B. Caffeine-induced expression of the proto-oncogene c-fos in rat striatum is increased after dopamine denervation. Acta Physiol. Scand. 149:1993;527-529.
205. Johansson B., Lindström K., Fredholm B.B. Differences in the regional and cellular localization of c-fos messenger RNA induced by amphetamine, cocaine and caffeine in the rat. Neuroscience. 59:1994;837-849.
206. 2A receptors in rat brain: comparison with dopamine receptors. Neuroscience. 80:1997;1187-1207.
207. Jolkkonen J., Jenner P., Marsden C.D. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res. Mol. Brain Res. 32:1995;297-307.
208. 2A receptor agonists and antagonists. Neuroscience. 85:1998;229-237.
209. 2A receptor antagonist. Brain Res. 800:1998;328-335.
210. Jonzon B., Fredholm B.B. Release of purines, noradrenaline and GABA from rat hippocampal slices by field stimulation. J. Neurochem. 44:1985;217-224.
211. Josselyn S.A., Beninger R.J. Behavioral effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmac. Biochem. Behav. 39:1991;97-103.
212. Joyce J.N., Sapp D.W., Marshall J.F. Human striatal dopamine receptors are organized in compartments. Proc. natl Acad. Sci. USA. 83:1986;8002-8006.
213. 2a) receptors. Brain Res. Dev. Brain Res. 94:1996;109-120.
214. Kaelin-Lang A., Lauterburg T., Burgunder J.M. Expression of adenosine A2a receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci. Lett. 261:1999;189-191.
215. 2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmac. 295:1996;147-154.
216. Kakiuchi S., Rall T.W., McIlwain H. The effect of electrical stimulation upon the accumulation of adenosine 3′,5′-phosphate in isolated cerebral tissue. J. Neurochem. 16:1968;485-491.
217. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmac. 256:1994;263-268.
218. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
219. 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 9:1998;2857-2860.
220. Kartzinel R., Shoulson I., Calne D.B. Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology. 26:1976;741-743.
221. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:1990;3421-3438.
222. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
223. 2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur. J. Pharmac. 287:1995;115-120.
224. 14C]-2-deoxyglucose autoradiographic study. J. Neurosci. 17:1997;4415-4425.
225. Kemp J.M., Powell T.P.S. The cortico-striate projection in the monkey. Brain. 93:1970;525-546.
226. 2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res. 756:1997;184-190.
227. 1 receptor and is dependent on NMDA stimulation. Brain Res. Mol. Brain Res. 23:1994;1-13.
228. King M.M., Huang C.Y., Chock P.B., Nairn A.C., Hemmings H.C. Jr., Chan K.P.J., Greengard P. Mammalian brain phosphoproteins as substrates for calcineurin. J. Biol. Chem. 259:1984;8080-8083.
229. 3H]acetylcholine release. J. Neurochem. 62:1994;960-966.
230. 3H]-CGS 21680 binding sites in the rat striatum and cortex. Br. J. Pharmac. 114:1995;537-543.
231. 2a receptor is not mediated by increases in cyclic AMP. J. Neurochem. 64:1995;2801-2809.
232. Kitai S.T., Kocsis J.D., Wood J. Origin and characteristics of the cortico-caudate afferents: an anatomical and electrophysiological study. Brain Res. 118:1976;137-141.
233. Klotz K.N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., Lohse M.J. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmac. 357:1998;1-9.
234. 2A receptor-mediated inhibition of calcium current in rat PC 12 cells via downregulation of protein kinase A. J. Physiol. 512:1998;351-363.
235. Konradi C., Kobierski L.A., Nguyen T.V., Heckers S., Hyman S.E. The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the preproenkephalin enhancer in rat striatum. Proc. natl Acad. Sci. USA. 90:1993;7005-7009.
236. Konradi C., Leveque J.C., Hyman S.E. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16:1996;4231-4239.
237. Krushel L.A., Fishell G., van der Kooy D. Pattern formation in the mammalian forebrain: striatal patch and matrix neurons intermix prior to compartment formation. Eur. J. Neurosci. 7:1995;1210-1219.
238. 2A receptors. Biochem. Pharmac. 57:1999a;65-75.
239. 2 receptors co-transfected in CHO cells. Biochem. Pharmacol. in press.
240. 2A receptor-mediated modulation of striatal GABA and ACh release. Br. J. Pharmac. 113:1994;43-48.
241. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66:1996;1882-1888.
242. 3H]CGS 21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res. 808:1998;320-323.
243. Labiner D.M., Butler L.S., Cao Z., Hosford D.A., Shin C., McNamara J.O. Induction of c-fos mRNA by kindled seizures: complex relationship with neuronal burst firing. J. Neurosci. 13:1993;744-751.
244. Lai H.L., Yang T.H., Messing R.O., Ching Y.H., Lin S.C., Chern Y. Protein kinase C inhibits adenylyl cyclase type VI activity during desensitization of the A2a-adenosine-receptor-mediated response. J. Biol. Chem. 272:1997;4970-4977.
245. 1 dopamine receptor in a subset of DARPP-32-containing neurons in rat caudate-putamen. Neuroscience. 78:1997;977-983.
246. 2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen. Pharmac. 27:1996;925-933.
247. Lau C.E., Falk J.L. Dose-dependent surmountability of locomotor activity in caffeine tolerance. Pharmac. Biochem. Behav. 52:1995;139-143.
248. Le F., Wilce P.A., Hume D.A., Shanley B.C. Involvement of gamma-aminobutyric acid and N-methyl-D-aspartate receptors in the inhibitory effect of ethanol on pentylenetetrazole-induced c-fos expression in rat brain. J. Neurochem. 59:1992;1309-1315.
249. Le F., Townsend-Nicholson A., Baker E., Sutherland G.R., Schofield P.R. Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. Biochem. Biophys. Res. Commun. 223:1996;461-467.
250. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. comp. Neurol. 355:1995;418-426.
251. Le Moine C., Normand E., Guitteny A.F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc. natl Acad. Sci. USA. 87:1990;230-234.
252. 1 dopamine receptor gene. Proc. natl Acad. Sci. USA. 88:1991;4205-4209.
253. 1 receptor-mediated effects on c-fos expression. J. Neurosci. 17:1997;8038-8048.
254. 2A receptor. Nature. 388:1997;674-678.
255. 2A receptors. Neurosci. Lett. 239:1997;61-64.
256. Libert F., Parmentier M., Lefort A., Dinsart C., Van Sande J., Maenhaut C., Simons M.J., Dumont J.E., Vassart G. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science. 244:1989;569-572.
257. 2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor. Genomics. 11:1991;225-227.
258. 2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience. 88:1999;1005-1008.
259. Lindskog, M., Svenningsson, P., Fredholm, B. B., Greengard, P., Fisone, G. (1999b) μ- and δ-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci., in press.
260. 1 and N-methyl-D-aspartate receptors. Proc. natl Acad. Sci. USA. 91:1994;8537-8541.
261. Lloyd H.G., Fredholm B.B. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem. Int. 26:1995;387-395.
262. Lloyd H.G., Lindström K., Fredholm B.B. Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation or energy depletion. Neurochem. Int. 23:1993;173-185.
263. Londos C., Cooper D.M., Wolff J. Subclasses of external adenosine receptors. Proc. natl Acad. Sci. USA. 77:1980;2551-2554.
264. Loopuijt L.D., van der Kooy D. Organization of the striatum: collateralization of its efferent axons. Brain Res. 348:1985;86-99.
265. 1 receptors initiates short-term synaptic depression in rat striatum. Neurosci. Lett. 199:1995;9-12.
266. 2 receptor agonist CGS 21680 on in vitro electrophysiology, cAMP formation and dopamine release in rat hippocampus and striatum. J. Pharmac. exp. Ther. 252:1990;1134-1141.
267. 2, receptor binding in the rat brain: an autoradiographic study. Synapse. 9:1991;95-102.
268. 2a adenosine receptor (ADORA2) to chromosome 22. Genomics. 20:1994;332-333.
269. 2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 173:1990;1169-1178.
270. Mailleux P., Verslype M., Preud'homme X., Vanderhaeghen J.J. Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain. Neuroreport. 5:1994;1265-1268.
271. Mally J., Stone T.W. The effect of theophylline on parkinsonian symptoms. J. Pharm. Pharmac. 46:1994;515-517.
272. 2A antagonists in the treatment of movement disorders. CNS Drugs. 10:1998;311-320.
273. Manzoni O.J., Manabe T., Nicoll R.A. Release of adenosine by activation of NMDA receptors in the hippocampus. Science. 265:1994;2098-2101.
274. 2 receptor control of pallidal fos expression: comparisons between intact and 6-hydroxydopamine-treated hemispheres. Brain Res. 632:1993;308-313.
275. 1 receptors, using in vivo and in vitro techniques. J. Pharmac. exp. Ther. 285:1998;1023-1030.
276. Martin G.E., Rossi D.J., Jarvis M.F. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmac. Biochem. Behav. 45:1993;951-958.
277. 2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience. 42:1991;697-706.
278. Mattera R., Graziano M.P., Yatani A., Zhou Z., Graf R., Codina J., Birnbaumer L., Gilman A.G., Brown A.M. Splice variants of the alpha subunit of the G protein Gs activate both adenylyl cyclase and calcium channels. Science. 243:1989;804-807.
279. 2 receptor interaction in globus pallidus. Synapse. 22:1996;132-138.
280. 2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J. Neurochem. 60:1993;2334-2337.
281. McGeorge A.J., Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
282. McIlwain H. Regulatory significance of the release and action of adenine derivatives in cerebral systems. Biochem. Soc. Symp. 36:1972;69-85.
283. 2a adenosine receptor from guinea pig brain. Neurochem. Res. 19:1994;613-621.
284. Merchant K.M. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol. Cell. Neurosci. 5:1994;336-344.
285. Mishra R.K., Gardner E.L., Katzman R., Makman M.H. Enhancement of dopamine-stimulated adenylate cyclase in rat caudate after lesions in the substansia nigra: evidence for denervation supersensitivity. Proc. natl Acad. Sci. USA. 71:1974;3883-3887.
286. 1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res. 710:1996;234-240.
287. 2a adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneimittelforschung. 44:1994;1296-1304.
288. Moratalla R., Robertson H.A., Graybiel A.M. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J. Neurosci. 12:1992;2609-2622.
289. Moratalla R., Vickers E.A., Robertson H.A., Cochran B.H., Graybiel A.M. Coordinate expression of c-fos and jun B is induced in the rat striatum by cocaine. J. Neurosci. 13:1993;423-433.
290. 2a receptor mRNA in neurochemically identified striatal neurons in the human compared to the rat. Soc. Neurosci. Abstr. 24:1998;161.1.
291. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmac. 251:1994;21-25.
292. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
293. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. A. Rev. Neurosci. 14:1991;421-451.
294. Morgan J.I., Cohen D.R., Hempstead J.L., Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science. 237:1987;192-197.
295. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16:1996;605-611.
296. Moser A., Liebetrau A., Cramer H. Adenosine receptor-coupled adenylate cyclase in the caudate nucleus of the rat brain. Neuropharmacology. 30:1991;769-773.
297. 2 receptor desensitization. Mol. Pharmac. 51:1997;991-998.
298. 2A receptors to agonist-induced desensitization. Br. J. Pharmac. 125:1998;347-356.
299. Murrin L.C., Gibbens D.L., Ferrer J.R. Ontogeny of dopamine, serotonin and spirodecanone receptors in rat forebrain-an autoradiographic study. Brain Res. 355:1985;91-109.
300. Nakajima T., Daval J.L., Morgan P.F., Post R.M., Marangos P.J. Adenosinergic modulation of caffeine-induced c-fos mRNA expression in mouse brain. Brain Res. 501:1989;307-314.
301. Nakki R., Sharp F.R., Sagar S.M., Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J. Neurosci. Res. 45:1996;13-27.
302. 2a receptor activation and is enhanced in parkinsonism. Soc. Neurosci. Abstr. 24:1998;648.2.
303. Nickell P.V., Uhde T.W. Dose-response effects of intravenous caffeine in normal volunteers. Anxiety. 1:1994;161-168.
304. 2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmac. exp. Ther. 259:1991;286-294.
305. Nisbet A.P., Foster O.J., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 66:1995;361-376.
306. Nishi A., Snyder G.L., Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17:1997;8147-8155.
307. 2-opioid agonists in rat caudate putamen. J. Neurochem. 65:1995;125-133.
308. 2a receptor ligand. J. Nucl. Med. 39:1998;498-503.
309. 2 receptor antagonist, to rat brain membranes. Mol. Pharmac. 46:1994;817-822.
310. Nörenberg W., Wirkner K., Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channel in a subset of rat neostriatal neurones. Br. J. Pharmac. 122:1997;71-80.
311. 2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons. Amino Acids. 14:1998;33-39.
312. 2-mediated attenuation of cortical excitation in nucleus accumbens neurons receorded in vitro. Brain Res. 634:1994;105-112.
313. 2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. 212:1996;53-56.
314. 2a adenosine receptors. J. Biol. Chem. 272:1997;337-344.
315. Olah M.E., Ren H., Stiles G.L. Adenosine receptors: protein and gene structure. Arch. Int. Pharmacodyn. Ther. 329:1995;135-150.
316. Olson L., Seiger Å., Fuxe K. Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. Brain Res. 44:1972;283-288.
317. 2 and dopamine autoreceptors antagonistically regulate tyrosine hydroxylase activity in rat striatal synaptosomes. Brain Res. 456:1988;302-309.
318. 2A receptors. Trends Pharmac. Sci. 17:1996;364-372.
319. 2A receptors and neuroprotection. Ann. NY Acad. Sci. 825:1997;30-48.
320. Ouimet C.C., Miller P.E., Hemmings H.C. Jr, Walaas S.I., Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 4:1984;111-124.
321. 2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry. 36:1997;832-838.
322. 2a adenosine receptor: delineation of multiple processes. Mol. Pharmac. 45:1994;1082-1094.
323. 2+ influx in PC 12 cells by involving protein kinase A. J. Neurochem. 68:1997;2177-2185.
324. 2A adenosine receptor in PC 12 cells. J. Neurochem. 71:1998;1251-1260.
325. 3H]-CGS 21680 as a ligand. Naunyn-Schmiedeberg's Arch. Pharmac. 342:1990;85-89.
326. 2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 65:1995;2057-2064.
327. 2a adenosine receptor gene. J. Neurochem. 66:1996;362-368.
328. 2a receptor mRNA expression in SH-SY5Y cells. Eur. J. Pharmac. 336:1997;71-80.
329. Phillis J.W., Kostopoulos G.K., Limacher J.J. A potent depressant action of adenine derivatives on cerebral cortical neurones. Eur. J. Pharmac. 30:1975;125-129.
330. 2b receptors from human brain. Biochem. Biophys. Res. Commun. 187:1992;86-93.
331. 2a adenosine receptors retain ligand binding. Mol. Pharmac. 45:1994;861-870.
332. 1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8:1996;1176-1181.
333. 2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. Brain Res. 759:1997;41-49.
334. 2A receptors in the induction of c-Fos expression by clozapine and haloperidol. Neuropsychopharmacology. 20:1999;44-51.
335. 2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience. 68:1995;721-728.
336. 1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res. 743:1996;124-130.
337. 2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res. 631:1993;161-166.
338. 2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur. J. Pharmac. 257:1994;21-25.
339. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmac. 287:1995;215-217.
340. 2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neurosci. Lett. 251:1998;201-204.
341. Porkka-Heiskanen T., Strecker R.E., Thakkar M., Bjorkum A.A., Greene R.W., McCarley R.W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 276:1997;1265-1268.
342. 2a selective adenosine receptor antagonist. Br. J. Pharmac. 115:1995;1096-1102.
343. Precht W., Yoshida M. Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. Brain Res. 32:1971;229-233.
344. 2+-sensitive adenylate cyclases. Mol. Pharmac. 13:1977;662-670.
345. 14C]-adenine and derivatives by cerebral tissues, superfused and electrically stimulated. Biochem. J. 126:1972;965-973.
346. 2 receptor subtypes in rat basal ganglia: a quantitative autoradiographic study. Brain Res. Dev. Brain Res. 60:1991;161-177.
347. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmac. Sci. 18:1997;338-344.
348. 2 receptors or nitric oxide? Brain Res. 743:1997;303-314.
349. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology. 17:1997;82-91.
350. 2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur. J. Pharmac. 347:1998;153-158.
351. 2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 49:1992;285-296.
352. Robertson G.S., Tetzlaff W., Bedard A., St-Jean M., Wigle N. c-fos mediates antipsychotic-induced neurotensin gene expression in rodent striatum. Neuroscience. 67:1995;325-344.
353. 2A receptor-containing neurons to GABAergic neurons in rat striatum. Soc. Neurosci. Abstr. 24:1998;821.6.
354. 2A receptors in the rat central nervous system. J. comp. Neurol. 401:1998;163-186.
355. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmac. Sci. 13:1992;439-445.
356. Ruskin D.N., Marshall J.F. Differing influences of dopamine agonists and antagonists on Fos expression in identified populations of globus pallidus neurons. Neuroscience. 81:1997;79-92.
357. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
358. 2a adenosine receptor mRNA expression by agonists and forskolin in PC 12 cells. Neuroreport. 5:1994;1317-1320.
359. 125I]iodosulpiride. Neuroscience. 28:1989;673-700.
360. Sarges R., Howard H.R., Browne R.G., Lebel L.A., Seymour P.A., Koe B.K. 4-Amino:1,2,4: triazolo:4,3-a:quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem. 33:1990;2240-2254.
361. 2 in rats. Proc. natl Acad. Sci. USA. 93:1996;5980-5984.
362. 2A receptor in sleep promotion. Eur. J. Pharmac. 351:1998;155-162.
363. Sattin A., Rall T.W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′ phosphate content of guinea pig cerebral cortex slices. Mol. Pharmac. 6:1970;13-23.
364. 2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience. 62:1994;65-85.
365. 2 receptor in the striatum: early localization in the patch compartment. J. comp. Neurol. 317:1992;117-128.
366. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13:1993;1080-1087.
367. 2 receptor in the rat striatum. Neurosci. Lett. 158:1993;121-124.
368. Schiffmann S.N., Vanderhaeghen J.J. Caffeine regulates neurotensin and cholecystokinin messenger RNA expression in the rat striatum. Neuroscience. 54:1993;681-689.
369. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
370. 2 receptor mRNA in the human brain. Neurosci. Lett. 130:1991;177-181.
371. Schiffmann S.N., Desdouits F., Menu R., Greengard P., Vincent J.D., Vanderhaeghen J.J., Girault J.A. Modulation of the voltage-gated sodium current in rat striatal neurons by DARPP-32, an inhibitor of protein phosphatse. Eur. J. Neurosci. 10:1998;1312-1320.
372. Schubert P., Komp W., Kreutzberg G.W. Correlation of 5′-nucleotidase activity and selective transneuronal transfer of adenosine in the hippocampus. Brain Res. 168:1979;419-424.
373. 2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 48:1996;167-189.
374. 2A-adenosine receptor in primary human endothelial cells. J. Biol. Chem. 272:1997;5792-5799.
375. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
376. Shi D., Nikodijevic O., Jacobson K.A., Daly J.W. Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell. Mol. Neurobiol. 13:1993;247-261.
377. 2A antagonists with potent anti-cataleptic activity. Bioorg. Med. Chem. 7:1997;2349-2352.
378. Shoulson I., Chase T. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology. 25:1975;722-724.
379. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387.
380. 1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18:1998;10297-10303.
381. Snyder S.H. Adenosine as a neuromodulator. A. Rev. Neurosci. 8:1985;103-124.
382. Snyder S.H., Katims J.J., Annau Z., Bruns R.F., Daly J.W. Adenosine receptors and behavioral actions of methylxanthines. Proc. natl Acad. Sci. USA. 78:1981;3260-3264.
383. Spencer H.J. Antagonism of cortical excitation of striatal neurons by glutamic acid diethyl ester: evidence for glutamic acid as an excitatory transmitter in the rat striatum. Brain Res. 102:1976;91-101.
384. 2-adenosine receptor subtype. Mol. Endocrinol. 6:1992;384-393.
385. Stein M.B., Black B., Brown T.M., Uhde T.W. Lack of efficacy of the adenosine reuptake inhibitor dipyramole in the treatment of anxiety disorders. Biol. Psychiat. 33:1993;647-650.
386. 2A receptors. Nucl. Med. Biol. 24:1997;187-191.
387. Stoof J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 294:1981;366-368.
388. 2 receptor-receptor interactions. Soc. Neurosci. Abstr. 24:1998;824.12.
389. Strömberg U., Waldeck B. Further studies on the behavioural and biochemical interaction between caffeine and L-DOPA. J. Neural. Transm. 34:1973;241-252.
390. Strömberg U., Waldeck B. Behavioural and biochemical interaction between caffeine and L-DOPA. J. Pharm. Pharmac. 25:1973;302-308.
391. Surmeier D.J., Eberwine J., Wilson C.J., Cao Y., Stefani A., Kitai S.T. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc. natl Acad. Sci. USA. 89:1992;10178-10182.
392. 1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron. 14:1995;385-397.
393. Suzuki F., Ishiwata K. Selective adenosine antagonists for mapping central nervous system adenosine receptors with positron emission tomography: Carbon-11 labeled KF15372 (A1) and KF17837 (A2A). Drug Develop. Res. 45:1998;312-323.
394. 2/3 receptor agonist on the expression of immediate early genes in globus pallidus. Neuropharmacology. 36:1997;1309-1317.
395. Svenningsson P., Johansson B., Fredholm B.B. Effect of different xanthines and phosphodiesterase inhibitors on c-fos expression in rat striatum. Acta Physiol. Scand. 154:1995;17-24.
396. Svenningsson P., Nomikos G.G., Fredholm B.B. Biphasic changes in locomotor behaviour and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J. Neurosci. 15:1995;7612-7624.
397. Svenningsson P., Ström A., Johansson B., Fredholm B.B. Increased expression of c-jun, junB, AP-1 and preproenkephalin mRNA in rat striatum following a single injection of caffeine. J. Neurosci. 15:1995;3583-3593.
398. Svenningsson P., Johansson B., Fredholm B.B. Caffeine-induced expression of c-fos mRNA and NGFI-A mRNA in caudate putamen and in nucleus accumbens are differentially affected by the N-methyl-D-asparate receptor antagonist MK-801. Brain Res. Mol. Brain Res. 35:1996;183-189.
399. Svenningsson P., Georgieva J., Kontny E., Heilig M., Fredholm B.B. Involvement of a c-fos-dependent mechanism in caffeine-induced expression of the preprotachykinin A and neurotensin/neuromedin N genes in rat striatum. Eur. J. Neurosci. 9:1997;2135-2141.
400. Svenningsson P., Hall H., Sedvall G., Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 27:1997;322-335.
401. 2A receptor messenger RNA in the rat central nervous sytem with special reference to dopamine innervated areas. Neuroscience. 80:1997;1171-1185.
402. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience. 79:1997;753-764.
403. 2A receptor mRNA in the primate striatum. J. comp. Neurol. 399:1998;229-240.
404. 1 receptors stimulates cAMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience. 84:1998;223-228.
405. Svenningsson P., Nergårdh R., Fredholm B.B. Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat. Neuropharmacology. 37:1998;331-337.
406. Svenningsson P., Fourreau L., Bloch B., Fredholm B.B., Gonon F., Le Moine C. Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons. Neuroscience. 89:1999;827-837.
407. Svenningsson P., Nomikos G.G., Fredholm B.B. The stimulatory action of caffeine is associated with alterations in gene expression in specific brain regions. J. Neurosci. 19:1999b;4011-4022.
408. Swanson L.W., Petrovich G.D. What is the amygdala? Trends Neurosci. 21:1998;323-331.
409. Thithapandha A., Maling H.M., Gillette J.R. Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations. Proc. Soc. exp. Biol. Med. 139:1972;582-586.
410. Todorov L.D., Mihaylova-Todorova S., Westfall T.D., Sneddon P., Kennedy C., Bjur R.A., Westfall D.P. Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation. Nature. 387:1997;76-79.
411. Torres G., Rivier C. Cocaine-induced expression of striatal c-fos in the rat is inhibited by NMDA receptor antagonists. Brain Res. Bull. 30:1993;173-176.
412. 2a agonists on amphetamine-induced locomotion and c-Fos in striatum and nucleus accumbens. Brain Res. 707:1996;75-80.
413. Ungerstedt U. Stereotaxic mapping of the monoamine pathway in the rat brain. Acta Physiol. Scand. Suppl. 367:1971;1-48.
414. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93.
415. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
416. Vargo J.M., Estrick M.S., Marshall J.F. Amphetamine-induced Fos expression in globus pallidus is altered by frontal cortex injury. Brain Res. 716:1996;207-212.
417. Vizi E.S., Knoll J. The inhibitory effect of adenosine and related nucleotides on the release of acetylcholine. Neuroscience. 1:1976;391-398.
418. Walaas S.I., Aswad D.W., Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 301:1983;69-71.
419. Waldeck B. Sensitization by caffeine of central catecholamine receptors. J. Neural. Transm. 34:1973;61-72.
420. 3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. J. Neurochem. 55:1990;1763-1771.
421. 1 receptors. J. Pharmac. exp. Ther. 275:1995;877-884.
422. Wang J.Q., McGinty J.F. Scopolamine augments C-FOS and ZIF/268 messenger RNA expression induced by the full D(1) dopamine receptor agonist SKF-82958 in the intact rat striatum. Neuroscience. 72:1996;601-616.
423. Ward R.P., Dorsa D.M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Neuroscience. 89:1999;927-938.
424. 2a adenosine receptor gene expression in developing rat brain. Brain Res. Mol. Brain Res. 20:1993;313-327.
425. White B.C., Simpson C.C., Adams J.E., Harkins D. Jr. Monoamine synthesis and caffeine-induced locomotor activity. Neuropharmacology. 17:1978;511-513.
426. Wilkening D., Makman M.H. 2-Chloroadenosine-dependent elevation of adenosine 3′,5′-cyclic monophosphate levels in rat caudate nucleus slices. Brain Res. 92:1975;522-528.
427. Williams T.C., Jarvis S.M. Multiple sodium-dependent nucleoside transport systems in bovine renal brush-border membrane vesicles. Biochem. J. 274:1991;27-33.
428. Wilson C.J., Groves P.M. Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular inject of horseradish peroxidase. J. comp. Neurol. 194:1980;599-615.
429. Winn H.R., Rubio R., Berne R.M. Brain adenosine concentration during hypoxia in rat. Am. J. Physiol. 241:1981;H235-H242.
430. 2 dopamine receptors on fos-like immunoreactivity in the normosensitive rat striatum. Brain Res. Bull. 35:1994;85-91.
431. 2 (long-form) receptor co-transfected mouse fibroblast cell-lines - studies on intracellular calcium levels. Neuroscience. 68:1995;729-736.
432. 3H]-5′-N-ethylcarboxamide adenosine binds to both Ra and Ri adenosine receptors in rat striatum. Naunyn-Schmiedeberg's Arch. Pharmac. 325:1984;218-225.
433. Yoshida M., Precht W. Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res. 32:1971;225-228.
434. 1 receptors. Proc. natl Acad. Sci. USA. 88:1991;1291-1295.
435. Young W.S. III, Bonner T.I., Brann M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. natl Acad. Sci. USA. 83:1986;9827-9831.
436. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730.
437. Yung K.K., Smith A.D., Levey A.I., Bolam J.P. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur. J. Neurosci. 8:1996;861-869.
438. Zarrindast M.R., Sharifzadeh M. Effects of adenosine drugs on apomorphine-induced licking in rats. Gen. Pharmac. 26:1995;1119-1123.
439. Zetterström T., Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur. J. Pharmac. 180:1990;137-143.
440. Zetterström T., Vernet L., Ungerstedt U., Tossman U., Jonzon B., Fredholm B.B. Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre. Neurosci. Lett. 29:1982;111-115.
441. Zimmermann H., Braun N., Kegel B., Heine P. New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem. Int. 32:1998;421-425.
442. 2A adenosine receptor antagonist. J. Pharmac. exp. Ther. 276:1996;398-404.